Drugs & Targets FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC June 03, 2022Vol.48 No.22
Capitol Hill House Republicans seek information on “me-too” drugs developed in China May 27, 2022Vol.48 No.21By Alice Tracey
Drugs & Targets FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC May 27, 2022Vol.48 No.21
Drugs & Targets FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML May 27, 2022Vol.48 No.21
Drugs & Targets Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer May 27, 2022Vol.48 No.21
Trials & Tribulations Cancer is complex and dynamic—ergo, dose optimization calls for mathematical modeling May 13, 2022Vol.48 No.19By Alexander Anderson, Robert Gillies and Robert Gatenby
Conversation with The Cancer Letter FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done May 06, 2022Vol.48 No.18By Matthew Bin Han Ong
Regulatory News Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand May 06, 2022Vol.48 No.18By Alice Tracey
Guest Editorial Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes May 06, 2022Vol.48 No.18By David Balis
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
